BELAB2122

beLAB2122 is a new multi-year partnership between some of the leading academic institutions of the Rhine-Main-Neckar region, Evotec and BMS to identify exciting and novel disease modifying therapeutic targets and platforms with the goal to develop these to new spinout companies. The name beLAB2122 refers to the Rhine, Main, and Neckar rivers, which connect the member institutions with one another and which total to 2,122 kilometres in length... beLAB2122 provides drug discovery resources and expertise, thereby significantly reducing timelines and ensuring a greater success rate for emerging therapeutic concepts to reach preclinical and clinical proof-of-concept. We catalyse innovation to create sustainable companies... be LAB2122 IS A PARTNERSHIP BETWEEN THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) HEIDELBERG, GERMAN CANCER RESEARCH CENTER (DKFZ) HEIDELBERG, GOETHE UNIVERSITY FRANKFURT, HEIDELBERG UNIVERSITY, UNIVERSITY OF TÜBINGEN, , BRISTOL MYERS SQUIBB AND EVOTEC SE, CREATED..

Registration numbers: HRB 72242 (W)

VAT numbers: DE 812 839 610

Primary location: Hamburg Germany